This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. A significant percentage of patients also reported reduced sleep disturbances by Week 16 in both clinicaltrials.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. As it establishes these new operations, SHL Medical will be welcomed into a growing community of lifesciences companies expanding in and around Charleston.
This initiative focuses on enhancing infrastructure to support the clinical and commercial-scale final assembly and packaging of drug-device combination products, emphasizing advanced drugdeliverysystems, particularly injectable formats.
For healthcare and lifesciences industries, Skin Cancer Awareness Month helps highlight the importance of preventive measures and early detection. is a biotech and lifesciences company dedicated to advancing the clinical development of innovative and groundbreaking therapeutic assets.
Related: Genentech’s New Ocular Implant DrugDeliverySystem for Macular Degeneration Could Be a Game Changer. Vuity’s formula is fast-acting, working as quickly as 15 minutes after administration and lasting for up to six hours. Importantly, it improves near and intermediate vision without affecting distance vision.
Filipe Rodrigues, MD/MSc, Medical Director at Medpace spoke about the modern-day applications of direct CNS administration, including intrathecal, intraparenchymal and ICV delivery. Vornov, the use of intrathecal delivery in drug development is unexplored for small molecules and peptides besides what has already been proved.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content